TO O 1004
Alternative Names: TO-O-1004Latest Information Update: 28 Aug 2026
At a glance
- Originator Theratocular Biotek
- Class Analgesics; Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Postoperative inflammation; Postoperative pain
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for preclinical development in Postoperative-inflammation in Taiwan (Ophthalmic, Drops)
- 28 Aug 2026 No recent reports of development identified for preclinical development in Postoperative-pain in Taiwan (Ophthalmic, Drops)
- 28 Jul 2022 TO O 1004 is available for licensing as of 28 Jul 2022. https://www.theratocular.com.tw/en/about.php